Research Analysts’ Weekly Ratings Changes for Amgen (AMGN)

Amgen (NASDAQ: AMGN) recently received a number of ratings updates from brokerages and research firms:

• 7/13/2026 – Amgen had its price target raised by UBS Group AG from $400.00 to $420.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Amgen had its price target raised by Guggenheim from $340.00 to $343.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Amgen had its price target lowered by Morgan Stanley from $340.00 to $333.00. They now have an “equal weight” rating on the stock.
• 7/7/2026 – Amgen had its price target raised by Truist Financial Corporation from $327.00 to $340.00. They now have a “hold” rating on the stock.
• 7/6/2026 – Amgen had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $350.00 price target on the stock.
• 7/1/2026 – Amgen had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $400.00 price target on the stock.
• 6/27/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/18/2026 – Amgen had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 6/18/2026 – Amgen had its “positive” rating reaffirmed by Royal Bank Of Canada.
• 6/16/2026 – Amgen had its price target raised by Mizuho from $295.00 to $303.00. They now have a “neutral” rating on the stock.
• 6/14/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/12/2026 – Amgen had its “overweight” rating reaffirmed by Piper Sandler.
• 6/9/2026 – Amgen had its price target raised by Morgan Stanley from $332.00 to $340.00. They now have an “equal weight” rating on the stock.
• 6/6/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/5/2026 – Amgen was given a new $389.00 price target by The Goldman Sachs Group, Inc..
• 5/23/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/20/2026 – Amgen had its price target lowered by Argus from $400.00 to $375.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.85% of the company’s stock.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.